161 related articles for article (PubMed ID: 35933231)
1. Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era.
Okumura K; Sogawa H; Samson D; Butler J; Veillette G; John D; Diflo T; Bodin R; Wolf DC; Latifi R; Nishida S
Transplant Proc; 2022 Sep; 54(7):1834-1838. PubMed ID: 35933231
[TBL] [Abstract][Full Text] [Related]
2. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era.
Shaikh A; Goli K; Lee TH; Rich NE; Benhammou JN; Keeling S; Kim D; Ahmed A; Goss J; Rana A; Singal AG; Kanwal F; Cholankeril G
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2288-2297.e4. PubMed ID: 36521738
[TBL] [Abstract][Full Text] [Related]
3. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
4. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
[TBL] [Abstract][Full Text] [Related]
5. Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction.
Ivanics T; Rizzari M; Moonka D; Al-Kurd A; Delvecchio K; Kitajima T; Elsabbagh AM; Collins K; Yoshida A; Abouljoud M; Nagai S
Am J Transplant; 2021 Mar; 21(3):1100-1112. PubMed ID: 32794649
[TBL] [Abstract][Full Text] [Related]
6. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
Kwong AJ; Kim WR; Flemming JA
Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
[TBL] [Abstract][Full Text] [Related]
8. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
9. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades.
Puigvehí M; Hashim D; Haber PK; Dinani A; Schiano TD; Asgharpour A; Kushner T; Kakked G; Tabrizian P; Schwartz M; Gurakar A; Dieterich D; Boffetta P; Friedman SL; Llovet JM; Saberi B
Am J Transplant; 2020 Jan; 20(1):220-230. PubMed ID: 31437349
[TBL] [Abstract][Full Text] [Related]
10. Are Hepatitis C Positive Female Liver Transplant Recipients Still at Increased Risk for Graft Failure? Reexamining the Disparity in the Modern Era of Direct-acting Antiviral Agents.
Yoeli D; Choudhury RA; Moore HB; Sauaia A; Simpson MA; Pomfret EA; Nydam TL
Transplantation; 2022 Jan; 106(1):129-137. PubMed ID: 33577252
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >20,000 patients.
Tabrizian P; Saberi B; Holzner ML; Rocha C; Kyung Jung Y; Myers B; Florman SS; Schwartz ME
HPB (Oxford); 2022 Jul; 24(7):1082-1090. PubMed ID: 34955348
[TBL] [Abstract][Full Text] [Related]
12. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
13. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
Young K; Liu B; Bhuket T; Gish RG; Wong RJ
J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
[TBL] [Abstract][Full Text] [Related]
14. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
Tanaka T; Voigt MD
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
[TBL] [Abstract][Full Text] [Related]
15. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma.
Ismail MS; Mohamed I; Polychronopoulou E; Goss JA; Kuo YF; Kanwal F; Jalal PK
J Hepatocell Carcinoma; 2021; 8():701-711. PubMed ID: 34235107
[TBL] [Abstract][Full Text] [Related]
17. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals.
Young K; Liu B; Bhuket T; Wong RJ
J Clin Exp Hepatol; 2020; 10(6):581-589. PubMed ID: 33311895
[TBL] [Abstract][Full Text] [Related]
18. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras.
Jacob JS; Shaikh A; Goli K; Rich NE; Benhammou JN; Ahmed A; Kim D; Rana A; Goss JA; Naggie S; Lee TH; Kanwal F; Cholankeril G
Clin Infect Dis; 2023 Feb; 76(4):592-599. PubMed ID: 36221143
[TBL] [Abstract][Full Text] [Related]
19. Indication for Liver Transplantation After Direct-Acting Agents in the Treatment of Patients With Hepatitis C.
Arias ABV; Villegas Herrera MT; Arco Sánchez A; Adel ME; Triguero Cabrera J; Plata Illescas C; Montes Osuna MC; Santoyo Villalba J; Villar Del Moral JM
Transplant Proc; 2022; 54(1):32-34. PubMed ID: 34911619
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
